DV
Dividend Vision

GUTS — Fractyl Health, Inc. Common Stock

Fractyl Health, Inc. Common Stock (GUTS)

Total return is -95.5% over the past 2.5 years, 159.0 points behind SPY at 63.5%. Its deepest 1-year drawdown was 83.4%.

Fractyl Health, Inc. is a metabolic therapeutics company developing treatments for type 2 diabetes and obesity, including the Revita DMR System, an outpatient procedural therapy that modifies duodenal function, and Rejuva, a gene therapy platform designed to alter pancreatic hormone function. The company does not currently distribute dividends. Fractyl Health appeals to investors with a higher risk tolerance seeking exposure to early-stage therapeutic development rather than current income generation.

GUTS key facts

Asset type
Stock
Asset class
Equity
Inception date
02/01/2024
Last close
$0.68
Market cap
$128,505,656
Average volume
740900.0
Beta
2.287
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.31